Shopping Cart
- Remove All
- Your shopping cart is currently empty
Zosuquidar (RS 33295-198) is a potent P-glycoprotein inhibitor with antitumor activity, inhibits tumor growth, significantly inhibits PD-L1 expression by triggering its autophagic degradation, and is used in the study of acute myeloid leukemia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.233 € | 1-2 weeks | |
50 mg | 1.822 € | 1-2 weeks | |
100 mg | 2.332 € | 1-2 weeks |
Description | Zosuquidar (RS 33295-198) is a potent P-glycoprotein inhibitor with antitumor activity, inhibits tumor growth, significantly inhibits PD-L1 expression by triggering its autophagic degradation, and is used in the study of acute myeloid leukemia. |
In vitro | Zosuquidar (0.3 μM, treated for 48 hours) enhances the cytotoxic effect of DNR (P-glycoprotein substrate) in P-glycoprotein-active cell lines. [2] Zosuquidar (5-16 μM, treated for 72 hours) alone exhibited strong cytotoxicity in drug-sensitive cell lines and multidrug resistant (MDR) cell lines. [1] |
In vivo | Intraperitoneal injection of 30, 10, 3, or 1 mg/kg Zosuquidar once daily for 5 days significantly prolonged subject survival. [1] Intraperitoneal injection of 30 mg/kg Zosuquidar once daily for 5 days observed a significant potentiation when combined with adriamycin (Doxorubicin). [1] |
Alias | RS33295-198, RS 33295-198, LY-335979, LY335979 |
Molecular Weight | 527.6 |
Formula | C32H31F2N3O2 |
Cas No. | 167354-41-8 |
Smiles | FC1(F)[C@]2([C@@]1(C=3C([C@@H](C=4C2=CC=CC4)N5CCN(C[C@H](COC=6C7=C(C=CC6)N=CC=C7)O)CC5)=CC=CC3)[H])[H] |
Relative Density. | 1.36 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (151.63 mM), Sonication is recommended | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.